Tetratherix Ltd (AU:TTX) — Market Cap & Net Worth
Market Cap & Net Worth: Tetratherix Ltd (TTX)
Tetratherix Ltd (AU:TTX) has a market capitalization of $178.16 Million (AU$251.80 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #17003 globally and #493 in its home market, demonstrating a 5.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tetratherix Ltd's stock price AU$4.96 by its total outstanding shares 50765665 (50.77 Million). Analyse Tetratherix Ltd operating cash flow efficiency to see how efficiently the company converts income to cash.
Tetratherix Ltd Market Cap History: 2025 to 2026
Tetratherix Ltd's market capitalization history from 2025 to 2026. Data shows growth from $117.82 Million to $178.16 Million (0.00% CAGR).
Tetratherix Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tetratherix Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
103.11x
Tetratherix Ltd's market cap is 103.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $117.82 Million | $1.14 Million | -$9.43 Million | 103.11x | N/A |
Competitor Companies of TTX by Market Capitalization
Companies near Tetratherix Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Tetratherix Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Tetratherix Ltd Historical Marketcap From 2025 to 2026
Between 2025 and today, Tetratherix Ltd's market cap moved from $117.82 Million to $ 178.16 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$178.16 Million | +51.22% |
| 2025 | AU$117.82 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Tetratherix Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $178.16 Million USD |
| MoneyControl | $178.16 Million USD |
| MarketWatch | $178.16 Million USD |
| marketcap.company | $178.16 Million USD |
| Reuters | $178.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tetratherix Ltd
Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical device in the areas of bone regeneration, tissue spacing, and tissue healing applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.